Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Crestor Generics To Launch After 12-Day Delay

Executive Summary

AstraZeneca's legal gambit results in almost two more weeks of sales for the statin even though the court ultimately agreed with FDA on labeling carve-out for orphan indication.

Advertisement

Related Content

FDA Nixes Innovator Industry-Backed Changes To Citizen Petition Rule
CVS Expands Formulary Exclusions In 2017, Express Scripts’ Tally Unchanged
CVS Expands Formulary Exclusions In 2017, Express Scripts’ Tally Unchanged
AstraZeneca CEO Says Post-Crestor Future On Track As Pipeline Builds
Crestor Generics On Hold As FDA, AstraZeneca Talk About Exclusivity
AstraZeneca Sues FDA On Crestor Generics: Fighting A 'Foregone Conclusion'?
Generic Crestor Marks The End Of An Era, Should Quickly Outperform PCSK9s

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS118812

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel